Introduction
Inflammatory bowel diseases (IBD) are a group of high-incidence inflammatory illness of the intestine, the two most prominent of which are ulcerative colitis (UC) and Crohn's disease (CD) [1] . Both share key clinical features (e.g., nausea, maldigestion and malnutrition, and associated extra-intestinal manifestations [2] ), but also differ in their predominant location and the type of inflammation (UC is restricted to the mucosa of the colon whereas CD affects the whole length of the gastrointestinal tract and all three layers of the epithelium).
There is increasing evidence that the common cause of IBD is a malfunction of the intestinal immune system and screening efforts support the existence of genetic susceptibility loci [3] , which may also affect treatment options and prognosis [4] .
P-glycoprotein (P-gp, MDR1)
P-glycoprotein (P-gp) is a 170 kDa transmembrane protein, member of the ATP binding cassette (ABC) family, and a well known mammalian efflux transporter that is expressed in many human organs with secretory or barrier function, including the liver, and the placenta [5] . It is also found on the endothelial capillaries of the brain [6] , thereby contributing to the blood-brain-barrier function. P-gp is considered to protect the cell from xenobiotics and toxic compounds and accepts a wide variety of substrates, ranging from small organic ions to amino acids and even macromolecules like polysaccharides [7, 8] . Other physiological functions are still subject of debate, but are thought to include regulation of apoptosis, stem-cell differentiation, cytokine modulation, and translocation of platelet-activating factor [9] .
Most SNPs in the coding region of P-gp have a relatively low frequency (<8%) [15] . With a reported prevalence of 34.3 % in Caucasians and 16.9 % in Asians, the SNP C3435T (exon 26) affecting the nucleotide binding domain (NBD) 2 is an exception [19] . Even though C3435T is a silent SNP, early studies [20] showed a decrease in duodenal MDR1 protein expression. Reasons for its effects are still subject of debate [21] and a possible link between this SNP and IBD is also inconclusive [12] .
The tri-allelic G2677T/A SNP (Ala893Ser/Thr), known to decrease MDR1 transport activity, is also frequently assessed. There are indications that the MDR1 G2677T allele is in linkage disequilibrium with C3435T, offering a possible explanation for loss of activity associated with this silent SNP [22] . MDR1 G2677A is not equally well understood as its prevalence is very low (around 1%) [12] and high sample sizes are needed to give valid estimates. Some authors therefore chose to exclude it in their studies [23, 24] .
Breast Cancer Resistance Protein (BCRP)
Breast cancer resistance protein (BCRP, ABCP, MXR) is the product of the ABCG2 gene, located on chromosome 4q22 and spanning > 66 kb. With reference to other dimer members of the ABC family of transporters, which consist of twelve transmembrane domains (TMD) and two ATP binding domains (ABD), BCRP has been characterized as a half-transporter, as it only has six TMDs and one ABD [25] . BCRP is expressed in the epithelium of the small intestine and small biliary ducts as well as in the breast and placenta [26] . Like P-gp, it is assumed to maintain functional barriers and has been shown to be a limiting factor in drug absorption and distribution, e.g. in topotecan, doxorubicin, and mitoxantrone [27, 28] .
The non-synonymous C421A SNP (Q141K) affects the ABD of BCRP and substrate binding properties [29] . Its prevalence is quite high, with about 30 % in Asian (particularly Han Chinese) and >10 % in Caucasian populations while it is rarely seen in African populations [30, 31] . Strikingly, no associations between the SNP and intestinal expression of mRNA or protein could be found [32] . In vitro and in vivo studies, on the other hand, have shown this SNP to be disruptive of BCRP activity. Clinical trials with diflomotecan, a novel anticancer agent inhibiting topoisomerase I, showed decreased plasma concentration in patients heterozygous for this SNP compared to wild type [33, 34] . Recently, the increased placental crossing of the antidiabetic agent glyburide (glibenclamide) has been demonstrated in stably transfected human embryonic kidney (HEK)-293 cells expressing the polymorphic ABCG2 (Q141K) [35] .
Synergisms of p-gp and BCRP
ABC transporters, and P-gp and BCRP in particular, play an important role in tissue defense. Both are highly expressed in so-called side population (SP) cells, a line of primitive cells derived from bone marrow stem cells. SP cells have been detected in non-hematopoietic tissue and the two efflux pumps are thought to contribute strongly to tissue defense and regeneration in many organs [36] . A further synergism between P-gp and BCRP lies in their overlapping substrate affinity, for example the anti-cancer agent doxorubicin [37] , the α 1 -receptor antagonist alfuzosin, and the histamine H2-receptor antagonist cimetidine [38] . Also, recent work by Tai et al. [39] indicates that both are involved in the clearance of the neurotoxic amyloid beta from the brain, thereby protecting individuals from Alzheimer's disease. It may suggest considering these two efflux pumps together in studies of pharmacokinetics or pathogenesis.
Haplotype studies
Haplotypes of MDR1 and BCRP have been reported to be associated with different inflammatory disorders of the gut. Urcelay et al. [40] , for example, have identified a susceptibility haplotype (2677T / G3435) for CD. Fiedler et al. [41] found a similar association, most notably for the MDR1 2677GG / 3435TT haplotype with UC, but not for CD. The haplotypes investigated by Ho et al. [23] showed positive (MDR1 G2677 / 3435T) and negative (MDR1 2677T / C3435) correlations with UC, and confirmed the findings of Fiedler et al. [42] Haplotypes including BCRP C421A have been less frequently assessed and no associations with a combined IBD endpoint are known of to date.
Methods and Materials Subjects
We recruited a total of 89 unrelated volunteers (54 female, 35 male; age: 49.9 years ± range; weight: 72.3 kg ± range; height: 1.68 m ±range; BMI: 25.5 kg/m 2 ± range) in a series of intestinal mucosa biopsies and blood samples taken between 2001 and 2007 as part of a regular diagnostic procedure. Diagnosis of UC and CD were according to current clinical knowledge and based on radiological, endoscopic, and histopathological assessment [43] . The study was approved by the local ethics committee (Ethik-Kommission Beider Basel, EKBB) and informed consent was obtained by all volunteers.
Genotyping
Genomic DNA was isolated from peripheral EDTA-blood using the QIAamp DNA blood Kit (Quiagen, Hilden, Germany). We performed TaqMan analysis on a 7900HT Sequence Detection System (Applied Biosystems, Rotkreuz, Switzerland). 1μl of 10 ng/ μl of genomic DNA was added in a well for a multiplex allelic discrimination assay along with 9 μl solution consisting of Applied Biosystems TaqMan MasterMix, forward primer, reverse primer, probes specific for the SNP being examined (see below), and RNase-free water. Samples were pipetted onto a 384-well PCR plate (Treff Lab ® ). The probe stock solutions (=100 pmol/µl) were diluted to a concentration of 2 pmol/µl for allelic discrimination analysis. During a run, samples were heated to 50°C for 2 minutes, then subjected to 95° C for initial denaturation. Then, 40 cycles of a two-step PCR were performed at 95° C for 15 s and 60° C for 60 s.
Primers and probes
The primer set for BCRP C421A was designed with Primer Express software (Version 2.0, Applied Biosystems) and ordered at Invitrogen (Carlsbad, CA, USA). The sequences for the probes were taken from work by Korenaga et al. [44] Table 1 . For MDR1 G2677T, a custom assay ordered from Applied Biosystems. The MDR1 C3435T SNP was assessed with primers and probes according to work by Eap et al. [45] .
Statistical analysis
We calculated the distribution of genotypes from the allele frequencies and compared our observations with distributions expected from an assumed Hardy-Weinberg equilibrium using Pearson's Χ 2 test with two degrees of freedom (df = 2). A p value < 0.05 was considered statistically significant. All evaluations were performed using Gnu R (http://r-project.org, version 2.8.1) on Microsoft Windows.
Results and Discussion

Determination of genotypes for BCRP C421A, MDR1 C3435T, and MDR1 G2677T
Distributions of all genotypes were calculated according to the Hardy-Weinberg equilibrium. We determined allele frequencies for the individual patient groups (CD, UC) and a combination of both patient groups (IBD). Odds ratios (OR) are given with a 95 % confidence interval (CI) (See Table 2 ).
MDR1 C3435T
Wild type and mutant alleles were distributed equally in healthy controls. This finding is in accordance with previously published studies [46] . A slight, but statistically insignificantly increased value of 54% in the mutant allele T was only seen in patients with UC (OR: 1.76, CI: 0.30 -9.78, p< 0.46). Glas et al. [47] and Potocnik et al. [24] have reported similar ratios. No difference was seen for CD (OR: 1.36, CI: 0.25 -6.50, p < 0.73) or the combined endpoint IBD (OR: 1.53, CI: 0.31 -6.20, p < 0.5).
MDR1 G2677T
Although this SNP is actually tri-allelic, we limited ourselves to the T mutant allele due to our relatively small sample size. Other groups have done the same [23, 24] . At 85%, the wild type allele was more prevalent than the mutant allele in healthy controls. Compared to this, an association was seen with the wild type allele in UC (93%, OR: 0.42, CI: 0.08 -2.20, p < 0.27) but no difference in either CD (OR: 0.65, CI: 0.15 -3.04, p < 0.52) or the combined endpoint IBD (OR: 0.53, CI: 0.14 -2.27, p < 0.33).
BCRP C421A
The wild type was far more abundant (94%) than the mutant allele. There is a clear trend towards the mutant allele in UC (OR: 3.51, CI: 0.63 -37.03, p < 0.18), albeit not a significant one. Patients with CD (OR: 1.68, CI: 0.27 -18.47, p < 0.71) and the combined group of IBD patients (OR: 2.48, CI: 0.50 -24.43, p< 0.35) showed a similar tendency towards the A allele. The lack of significance may be due to the small sample population size and hence low statistical power.
Haplotype analysis
We investigated the associations of combined haplotypes of MDR1 and BCRP SNPs with special attention to the haplotypes previously reported on by other authors [40, 41, 45] . Most strikingly, we found no occurrence of the MDR 1*2 haplotype within any of the subgroups. The strongest association of a BCRP haplotype was for homozygous MDR1 3435CC / BCRP 421CC (Χ 2 : 1.0142, p < 0.30) in UC and MDR1 2677G / BCRP 421A (Χ 2 : 1.5615, p < 0.22), also in UC. It should be stressed that the latter combinations of loci are haplotypes only in a looser definition of the term as they are spread over different chromosomes.
Conclusions
We investigated the prevalence of the SNPs MDR1 C3435T, MDR1 G2677T, and BCRP C421A in blood samples from a Swiss population of healthy volunteers and patients suffering from CD or UC. Genotype and allele frequencies are similar to those found in other European populations. Although the effect of BCRP C421A on IBD is still poorly understood, the mutant allele showed the strongest correlation with UC of all SNPs in this article. An analysis in a larger sample of the population may reveal a statistically significant connection.
In our survey of haplotypes, we found no cases of MDR1 2677T / G3435. However, our results justify further research of the prevalence of the haplotypes MDR1 C3435T / BCRP C421A and MDR1 G2677T / BCRP C421A, both of which were weakly associated with susceptibility to UC. Again, a larger sample size would be desirable.
Data on the role of BCRP C421A in disease pathogenesis is still scarce, although this is increasingly coming into focus. Its pathogenetic potential has been recently demonstrated in a study in the Han Chinese population, showing a strong association between C421A and susceptibility to gout [48] . On the other hand, no association with the risk for colorectal cancer (for which UC are a known risk factor) could be demonstrated in an analysis of the Danish population [49] . The effects of BCRP C421A in disease remain ambivalent.
MDR1 as a candidate gene has received more attention in the past. In line with our findings of a weak association of the wild type 2677G is a current analysis of the Canterbury IBD project [50] . Ardizzone et al. [51] found no overall correlation of MDR1 C3435T or G2677T with IBD. They did, however, show an association of C3435T a subtype of CD (ileo-colonic CD). This selective analytical subgroup approach seems very sensible, given the generally weak associations of single genetic variants or haplotypes, as a way to increase sensitivity without the need of very large sample sizes. Unfortunately, the clinical information available to us was not detailed enough to allow for such an analysis. This, of course, is largely due to the size of the general Swiss population itself. Drawing greater sample sizes would involve a considerably longer sampling period and involvement of more centers on the national level. It is questionable that sufficient homogeneity as to stage of disease, treatment history, and so on, can be achieved in such a small population.
The etiology and pathogenesis of IBD remains poorly understood. The many factors known to influence disease susceptibility and phenotype cannot be pinned down to any single SNP, nor is any haplotype likely to discriminate the many facets of these diseases [52] . However, knowledge of the activity of efflux transporters at various stages of disease and in different populations will ultimately aid in the pathogenetic understanding and improved individualized therapy based on pharmacogenetic principles. Further studies could focus on patient subgroups based on disease progression and response to treatment.
